(Q43027653)

12 November 2017

Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

Kathleen E Squires

1

1 reference

12 November 2017

Benjamin Young

2

1 reference

12 November 2017

Edwin DeJesus

3

1 reference

12 November 2017

Nicholas Bellos

4

1 reference

12 November 2017

Daniel Murphy

5

1 reference

12 November 2017

Denise H Sutherland-Phillips

6

1 reference

12 November 2017

Henry H Zhao

7

1 reference

12 November 2017

Lisa G Patel

8

1 reference

12 November 2017

Lisa L Ross

9

1 reference

12 November 2017

Paul G Wannamaker

10

1 reference

12 November 2017

Mark S Shaefer

11

1 reference

12 November 2017

ARIES Study Team

12

1 reference

12 November 2017

1 March 2010

1 reference

12 November 2017

1 reference

12 November 2017

11

1 reference

12 November 2017

2

1 reference

12 November 2017

69-79

1 reference

Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras

12 November 2017

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Decline in the AIDS and death rates in the EuroSIDA study: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Toxicity of antiretroviral therapy and implications for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Genetic variations in HLA-B region and hypersensitivity reactions to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

Once-daily abacavir/lamivudine and ritonavir-boosted atazanavir for the treatment of HIV-1 infection in antiretroviral-naïve patients: a 48-week pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FHCT1102-69

21 January 2018

Identifiers

DOI

10.1310/HCT1102-69

1 reference

12 November 2017

1 reference